{"id":"W4200502653","doi":"10.1097/qad.0000000000003025","title":"Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","year":2021,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Rilpivirine; Tolerability; Regimen; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Phases of clinical research; Adverse effect; Clinical trial; Virology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005446546,0.001395614,0.001248328,0.0002665513,0.0004707207,0.001146662,0.000768665,0.0009691364,0.005939808],"category_scores_gemma":[0.003472059,0.0004362163,0.002039911,0.0003208759,0.0007096519,0.0008781131,0.0005388444,0.002789548,0.00129485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00067225,"about_ca_system_score_gemma":0.001793932,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007184604,"about_ca_topic_score_gemma":0.00154784,"domain_scores_codex":[0.9984339,0.0008601588,0.00013303,0.0002202895,0.0002012361,0.000151346],"domain_scores_gemma":[0.997253,0.0005310422,0.0007730526,0.0003867816,0.000321353,0.000734741],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8763952,0.03703031,0.01262134,0.0005167011,0.002019738,0.0001772238,0.0002818428,0.00205168,0.02393327,0.0001388387,0.003278488,0.04155548],"study_design_scores_gemma":[0.3438564,0.5888784,0.04781072,0.00007287726,0.001631049,0.0003680763,0.000137868,0.001687493,0.009081966,0.0003317201,0.00605221,0.00009128382],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896006,0.0007623498,0.001049088,0.0001851734,0.0001062848,0.003364118,0.002699777,0.00008120769,0.002151377],"genre_scores_gemma":[0.9852011,0.0004968711,0.002693211,0.0004490472,0.00008695744,0.004242143,0.003957569,0.00004433539,0.00282882],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005939808,"threshold_uncertainty_score":0.02880448,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07318126596459043,"score_gpt":0.3788883562795782,"score_spread":0.3057070903149878,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}